Affimed (AFMD) Competitors

2seventy bio (NASDAQ:TSVT) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation.

Which has more volatility & risk, TSVT or AFMD?

2seventy bio has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500.

Does the MarketBeat Community believe in TSVT or AFMD?

Affimed received 410 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 70.16% of users gave Affimed an outperform vote while only 56.82% of users gave 2seventy bio an outperform vote.

Company	Underperform	Outperform
2seventy bio	Outperform Votes 25 56.82%	Underperform Votes 19 43.18%
Affimed	Outperform Votes 435 70.16%	Underperform Votes 185 29.84%

Which has preferable earnings & valuation, TSVT or AFMD?

Affimed has lower revenue, but higher earnings than 2seventy bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
2seventy bio	$100.39M	2.47	-$217.57M	-$4.35	-1.11
Affimed	$2.68M	23.66	-$114.66M	N/A	N/A

Do insiders and institutionals hold more shares of TSVT or AFMD?

93.9% of 2seventy bio shares are owned by institutional investors. Comparatively, 30.8% of Affimed shares are owned by institutional investors. 7.2% of 2seventy bio shares are owned by insiders. Comparatively, 3.8% of Affimed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media favor TSVT or AFMD?

In the previous week, 2seventy bio and 2seventy bio both had 1 articles in the media. 2seventy bio's average media sentiment score of 1.87 beat Affimed's score of 0.80 indicating that 2seventy bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
2seventy bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Affimed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is TSVT or AFMD more profitable?

2seventy bio has a net margin of -354.16% compared to Affimed's net margin of -2,922.74%. 2seventy bio's return on equity of -66.01% beat Affimed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
2seventy bio	-354.16%	-66.01%	-29.65%
Affimed	-2,922.74%	-155.30%	-92.65%

Do analysts prefer TSVT or AFMD?

2seventy bio currently has a consensus price target of $9.00, indicating a potential upside of 90.68%. Affimed has a consensus price target of $32.50, indicating a potential upside of 679.38%. Given Affimed's stronger consensus rating and higher probable upside, analysts clearly believe Affimed is more favorable than 2seventy bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
2seventy bio	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Affimed	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

2seventy bio beats Affimed on 8 of the 15 factors compared between the two stocks.